Psychopharmacology

, Volume 87, Issue 3, pp 266–271

Cholinergic modulation of memory in rats

  • Vahram Haroutunian
  • Edward Barnes
  • Kenneth L. Davis
Original Investigations

Abstract

Central cholinergic systems have long been implicated in the modulation of learning and memory processes in animals and man. Drugs that affect the central cholinergic system have been found either to enhance or to hinder performance in tests of learning and memory. Few studies have evaluated the effects of different cholinergic drugs within a single experimental paradigm and with a relatively wide dose range. The studies reported here investigated the effects of cholinergic drugs with diverse modes of action on the retention of a passive avoidance response. Physostigmine, arecoline, oxotremorine, nicotine, and 4-aminopyridine were administered IP immediately following the acquisition of a one-trial passive avoidance task. All of the drugs were found to enhance 72-h retention of passive avoidance; however, the effective doses were different for each of the drugs studied.

Key words

Cholinergic Avoidance Memory Physostigmine Arecoline Oxotremorine Nicotine 4-Aminopyridine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anden NE, Leander S (1979) Effects of 4-aminopyridine on the turnover of the monoamines in the central nervous system of the rat. J Neural Transm 44:1–12Google Scholar
  2. Bammer G (1982) Pharmacological investigations of neurotransmitter involvement in passive avoidance responding: a review and some new results. Neurosci Biobehav Rev 6:247–296Google Scholar
  3. Baratti CM, Huygens P, Mino J, Merlo A, Gardella J (1979) Memory facilitation with posttrial oxotremorine and physostigmine in mice. Psychopharmacology 64:85–88Google Scholar
  4. Baratti CM, Introini IB, Huygens P, Gusovsky F (1983) Possible cholinergic-dopaminergic link in memory facilitation induced by oxotremorine in mice. Psychopharmacology 80:161–165Google Scholar
  5. Bartus RT (1979) Four stimulants of the central nervous system: effects on short term memory in young versus aged monkeys. J Am Geriat Soc 27:289–297Google Scholar
  6. Bartus RT, Dean RL, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–417Google Scholar
  7. Bartus RT, Dean RL, Beer B (1980) Memory deficits in aged cebuo monkeys and facilitation with central cholinomimetics. Neurobiology of Aging 1:145–152Google Scholar
  8. Battig K (1970) The effects of pre- and post-trial application of nicotine on the 12 problems of the Hebb-Williams-Test in the rat. Pschopharamcologia 18:68–76Google Scholar
  9. Bures J, Bohdenecky Z, Weiss T (1962) Physostigmine induced hippocampal theta activity and learning in rats. Psychopharmacologia 3:254–263Google Scholar
  10. Cheney DL, costa E (1977) Pharmacological implications of brain acetylcholine turnover measurements in rat brain nuclei. Ann Rev Pharmacol Toxicol 369–386Google Scholar
  11. Cox T, Tye N (1973) Effects of physostigmine on the acquisition of a position discrimination in rats. Neuropharmacology 12:477–484Google Scholar
  12. Coyle JT, Price DL, Delong MR (1983) Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 219:1184–1190Google Scholar
  13. Davis KL, Mohs RC, Tinklenberg JR, Pfefferbaum A, Hollister LE, Kopell BS (1978) Physostigmine: Improvement on long-term memory processes in normal subjects. Science 201:272–274Google Scholar
  14. Deutsch JA, Rogers JB (1979) Cholinergic excitability and memory: animal studies and their clinical implications. In: Davis KL, Berger PA (eds) Brain acetylcholine, and neuropsychiatric disease, Plenum Press, New York, pp 175–204Google Scholar
  15. Dilts SC, Berry CA (1967) Effect of cholinergic drugs on passive avoidance in the mouse. J Pharmacol Exp Ther 158:279–285Google Scholar
  16. Essman WB, Essman SG (1971) Cholinergic mechanisms and avoidance behavior acquisition: effects of nicotine in mice. Psychol Rep 29:987–993Google Scholar
  17. Flood JF, Smith GG, Cherkin A (1983) Memory retention: Potentiation of cholinergic drug combinations in mice. Neurobiology of Aging 4:37–43Google Scholar
  18. Flood JF, Landry DW, Jarvik M (1981) Cholinergic receptor interactions and their effects on long-term processing. Brain Res 215:177–185Google Scholar
  19. Folgering H, Rutten J, Agoston S (1979) Stimulation of phrenic nerve activity by an acetylcholine releasing drug 4-aminopyridine. Pflugers Arch 379:181–185Google Scholar
  20. Freeman SE (1979) Cholinergic mechanisms in heart: interactions with 4-aminopyridine. J Pharmacol Exp Ther 210:7–14Google Scholar
  21. Garg M, Holland HC (1969) Consolidation and maze learning: A study of some strain/drug interactions. Psychopharmacologia 14:426–431Google Scholar
  22. Glover WE (1981) Cholinergic effect of 4-aminopyridine and adrenergic effects of 4-methyl-2-aminopyridine in cardiac muscle. Eur J Pharmacol 71:21–31Google Scholar
  23. Gold PE, Zornetzer SF (1983) the mnemon and its juices: neuromodulation of memory processes. Behav Neural Biol 38:151–189Google Scholar
  24. Haroutunian V, Kanof P, Davis KL (1985) Pharmacological alleviations of cholinergic lesion induced memory deficits in rats. Life Sci (in press)Google Scholar
  25. Hunter B, Zornetzer SF, Jarvik ME, McGaugh JL (1977) Modulation of learning and memory: effects of drugs influencing neurotransmitters. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of Psychopharmacology, Vol 8, Plenum Press, New York, pp 531–577Google Scholar
  26. Karczmar AG (1979) Brain acetylcholine and animal electrophysiology. In: Davis KL, Berger PA (eds) Brain acetylcholine and neuropsychiatric disease, Plenum Press, New York, pp 269–310Google Scholar
  27. Lundh H, Nilsson O, Rosen I (1977) 4-Aminopyridine — a new drug tested in the treatment of Eaton-Lambert syndrome. J Neurol Neurosurg Psychiatr 40:1109–1112Google Scholar
  28. Lundh H, Thesleff S (1977) The mode of action of 4-aminopyridine and guanidine on transmitter release from motor nerve terminals. Eur J Pharmacol 42:411–412Google Scholar
  29. Merves H, Pichon Y (1977) The effect of internal and external 4-aminopyridine on the potassium currents of the intracellularly perfused squid giant axon. J Physiol (Lond) 268:511–532Google Scholar
  30. Perry EK, Blessed KG, Tomlinson BE, Perry RH, Crow TJ, Cross AJ, Dockray GT, Dimaline R, Arregui A (1981) Neurochemical activities in human temporal lobe related to aging and Alzheimer's type changes. Neurobiology of Aging 2:251–256Google Scholar
  31. Pepeu G (1974) The release of acetylcholine from the brain: An approach to the study of central cholinergic mechanisms. In: Kerkut GA, Phillis JW (eds) Progress in neurobiology, Pergamon Press, Oxford, pp 257–288Google Scholar
  32. Ringdahl B, Jenden DJ (1983) Pharmacological properties of oxotremorine and its analogs. Life Sci 32:2402–2413Google Scholar
  33. Russell RW (1982) Cholinergic systems in behavior: the search for mechanisms of action. Ann Rev Pharmacol Toxicol 22:435–463Google Scholar
  34. Simmons MA, Dun NJ (1984) Actions of 4-aminopyridine on mammalian ganglion cells. Brian Res 298:149–153Google Scholar
  35. Sitaram N, Weingartner H, Gillin JC (1978) Human serial learning enhancement with arecoline (sic) and impairment with scopolamine. Science 201:274–276Google Scholar
  36. Stratton LD, Petrinovich LF (1963) Post-trial injection of an anticholinesterase drug and maze learning in two strains of mice. Psychopharmacologia 5:47–54Google Scholar
  37. Vizi ES, van Dijk J, Foldes FF (1977) The effect of 4-aminopyridine on acetylcholine release. J Neural Transm 41:265–274Google Scholar
  38. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR (1982) Alzheimer's disease and senile dementia; loss of neurons in the basal forebrain. Science 215:1237–1239Google Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • Vahram Haroutunian
    • 1
  • Edward Barnes
    • 1
  • Kenneth L. Davis
    • 1
    • 2
  1. 1.Department of PsychiatryBronx VA Medical CenterBronxUSA
  2. 2.Dept. of Psychiatry and PharmacologyMount Sinai School of MedicineNew YorkUSA

Personalised recommendations